Clinical trial NCT02430363: Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475
Official title: Phase IIb Trial Evaluations Of The Effectiveness Of Treatment Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (Pembrolizumab)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Glioblastoma
Keywords: pembrolizumab
MK-3475
Glioblastoma
Gliosarcoma
Suppressor of the PI3K/Akt pathways
Pictilisib
GDC-0941
BEZ235
NVP-BEZ235
Ipatasertib
GDC-0068
Lead sponsor: Medical Research Council
Sponsor class: OTHER_GOV
Collaborators: name: Aarhus University Hospital
name: NCRI Clinical Studies Groups
name: ECCO - the European CanCer Organisation
name: Merck Sharp & Dohme LLC
First posted: 2015-04-30
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: It is known that after application of MK-3475 activated PD -1 negatively regulates the activation of T cells through suppression of the path of PI3K / Akt.

This study will identify the effectiveness of oral inhibitors of PI3K / Akt pathway in comparison with MK-3475 (pembrolizumab).

Detailed description: A humanized monoclonal IgG4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immunopotentiating activity. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include PD-L1, which is expressed on antigen presenting cells (APCs) and overexpressed on certain cancer cells, and PD-L2, which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation through the suppression of the PI3K/Akt pathway.

This study will identify the effectiveness of oral inhibitors of PI3K / Akt pathway in comparison with MK-3475 (pembrolizumab).

Eligibility criteria: Inclusion Criteria:

* Have histologically confirmed World Health Organization Grade IV malignant glioma (glioblastoma or gliosarcoma). Participants will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or variants is made.
* Previous first line therapy with at least radiotherapy and temozolomide
* Be at first or second relapse.
* Participants must have shown unequivocal evidence for tumor progression by MRI or CT scan.
* CT or MRI within 14 days prior to start of study drug.
* An interval of at least 4 weeks (to start of study agent) between prior surgical resection or one week for stereotactic biopsy.
* An interval of at least 12 weeks from the completion of radiation therapy to start of study drug unless there is a new area of enhancement consistent with recurrent tumor outside the radiation field or there is unequivocal histologic confirmation of tumor progression
* Participants must have recovered to grade 0 or 1 or pre-treatment baseline from clinically significant toxic effects of prior therapy (including but not limited to exceptions of alopecia, laboratory values listed per inclusion criteria, and lymphopenia which is common after therapy with temozolomide).
* From the projected start of scheduled study treatment, the following time periods must have elapsed: 5 half-lives from any investigational agent, 4 weeks from cytotoxic therapy (except 23 days for temozolomide and 6 weeks from nitrosoureas), 6 weeks from antibodies, or 4 weeks (or 5 half-lives, whichever is shorter) from other anti-tumor therapies.
* Payment of charitable contributions may be required

Exclusion Criteria:

* Current or planned participation in a study of an investigational agent or using an investigational device.
* Has a diagnosis of immunodeficiency.
* Has tumor primarily localized to the brainstem or spinal cord.
* Has presence of diffuse leptomeningeal disease or extracranial disease.
* Has received systemic immunosuppressive treatments within 6 months of start of study drug
* Requires treatment with high dose systemic corticosteroids defined as dexamethasone \> 4 mg/day or bioequivalent for at least 3 consecutive days within 2 weeks of start of study drug.
* Has received prior interstitial brachytherapy, implanted chemotherapy, stereotactic radiosurgery or therapeutics delivered by local injection or convection enhanced delivery.
* Requires therapeutic anticoagulation with warfarin at baseline; patients must be off warfarin or warfarin-derivative anti-coagulants for at least 7 days prior to starting study drug; however, therapeutic or prophylactic therapy with low-molecular weight heparin is allowed.
* Has history of known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhage within 12 months of start of study drug
* Has evidence of intratumoral or peritumoral hemorrhage on baseline MRI scan other than those that are grade ≤ 1 and either post-operative or stable on at least 2 consecutive MRI scans.
* Has gastrointestinal bleeding or any other hemorrhage/bleeding event CTCAE Grade \> 3 within 6 months of start of study drug.
* Has a known additional malignancy that is progressing or requires active treatment within 3 years of start of study drug. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
* Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.
* Has evidence of interstitial lung disease or active, non-infectious pneumonitis.
* Has an active infection requiring systemic therapy.
* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
* Is pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial
* Has a known history of HIV
* Has known active Hepatitis B or Hepatitis C
* Has received a live vaccine within 30 days prior to the first dose of study drug.
* Has a known hypersensitivity to any of the study therapy products.
* Has received anti-angiogenic or anti-VEGF targeted agents (e.g. bevacizumab, cediranib, aflibercept, vandetanib, XL-184, sunitinib, etc)
* Has a history of non-healing wounds or ulcers, or bone refractures within 3 months of fracture
* Has a history of arterial thromboembolism within 12 months of start of study drug.
* Has inadequately controlled hypertension
* Has a history of hypertensive crisis or hypertensive encephalopathy
* Has had clinically significant cardiovascular disease within 12 months of start of study drug
* Has a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to start of study drug.

Primary outcomes:
measure: Progression Free Survival
timeFrame: Time Frame: 12 months
Secondary outcomes:
measure: Safety and tolerability of Pembrolizumab (Assessed by reported adverse events using CTCAE version 4.0)
timeFrame: Time Frame: 12 months
Other outcomes:
measure: Safety and tolerability of inhibitors PI3K/Akt pathways as monotherapy (adverse events using CTCAE version 4.0)
timeFrame: Time Frame: 12 months
Locations:
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
city: Houston
country: United States
facility: M D Anderson Cancer Center
state: Texas
city: Brussels
country: Belgium
facility: UCL- Cliniques Universitaires Saint Luc
city: Duisburg
country: Germany
facility: St Johannes Hospital
city: Brescia
country: Italy
facility: Spedali Civili di Brescia
city: Milan
country: Italy
facility: IRCCS San Raffaele
city: Wroclaw
country: Poland
facility: Lower-Silesian Oncology Centre
state: Lower-Silesian
city: St. Petersburg
country: Russian Federation
facility: Pavlov State Medical University
city: Barcelona,
country: Spain
facility: Hospital Universitario Germans Trias I Pujol
city: Bern
country: Switzerland
facility: Universitätsklinik für Frauenheilkunde
city: Dnepropetrovsk
country: Ukraine
facility: Regional Cancer Center
city: Kiev
country: Ukraine
facility: National Institute of Cancer
city: Belfast
country: United Kingdom
facility: Royal Victoria Hospital
state: Ulster
Study officials:
affiliation: MRC Clinical Trials Unit
name: Jann Lee, PhD
role: PRINCIPAL_INVESTIGATOR
References: